NeuroMab™ Anti-TDP43 Antibody(NRP-0422-P715)

Product Overview

Description

The anti-TDP-43 antibody can be used to diagnose, prevent, alleviate and/or treat a disease, disorder and/or abnormality associated with TDP-43 aggregates including but not limited to Frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), Parkinson's disease (PD), Chronic Traumatic Encelopathy (CTE), and limbic-predominant age-related TDP-43 encephalopathy (LATE).

Immunogen

full length TDP-43 (FL TDP-43)

Species Reactivity

Human

Clonality

Monoclonal

Host Species

Mouse

Applications

WB; IHC; ELISA; In Vitro; In Vivo

Relevant Diseases

Amyotrophic Lateral Sclerosis

Product Properties

Formulation

PBS only

Preservatives

BSA Free

Concentration

1mg/mL

Purification

Purified recombinant IgG prepared by affinity chromatography on Protein A from a mammalian cell line

Purity

>95% by SDS PAGE or HPLC

Endotoxin Level

Regular Endotoxin < 5 EU/mg
Low Endotoxin < 1 EU/mg

Shipping

Gel Packs

Storage

Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.

Research Use Only

For research use only

Target

TDP43

Official Name

TDP-43

Full Name

TAR DNA binding protein

Alternative Names

TDP-43; TAR DNA binding protein

Gene ID

23435(Human); 230908(Mouse); 298648(Rat)

Uniprot ID

Q13148(Human); Q921F2(Mouse)

Product Pictures

ELISA

Figure 1 TDP-43 levels in CSF of various FTLD-TDP patients and healthy controls using the AlphaLISA assay for ACI-7069-633B12-AM (IgG2a variant) and ACI-7071-809F12-Abl (IgG2a variant) Quantify.

The endpoint after 30 h was normalized to the isotype control (gray bars) and the percent aggregated TDP-43 was calculated for ACI-7069-633B12-AM (dashed gray bars). Mean ± SD of three independent experiments are shown and statistical differences between isotype control and ACI-7069-633B12-AM (IgG2a variant) were analyzed by Welch's t-test (*** p < 0.001).

Publications